A database of publications about African genetic resources and digital sequence information — real bibliographic metadata pulled from PubMed, with a durable link back to the source record. Papers that aren't on PubMed, given by curators as evidence, are listed beside them from Crossref, linked by their DOI to the publisher. Full text is frequently paywalled even when the abstract/metadata is open, so this is a metadata catalog with an outbound link, not a hosted archive; this platform never claims to host or redistribute full text.
Elafibranor in primary biliary cholangitis: two-year placebo-controlled outcomes and long-term open-label data from the ELATIVE® phase III trial.
Kowdley KV, Bowlus CL, Levy C, Akarca U, Alvares-da-Silva MR, Andreone P, Arrese M, Corpechot C, Elbeshbeshy H, Francque S, Heneghan MA, Invernizzi P, Jacobson IM, Jones D, Kremer AE, Kruger FC, Kugelmas M, Lawitz E, Mayo MJ, Shiffman ML, Sonderup M, Swain MG, Valera JM, Vierling JM, Villagrasa A, Villamil A, Antunes N, Raskino C, Sleiman M, Cranham V, Miller B, Schattenberg JM · J Hepatol (2026)
South Africa · DOI: 10.1016/j.jhep.2026.08.016
We report 104-week placebo-controlled data and long-term open-label extension (OLE) data from the ongoing ELATIVE® phase III trial (NCT04526665) of elafibranor in primary biliary cholangitis (PBC).
A total of 161 patients were randomized 2:1 to elafibranor 80 mg or placebo. The double-blind period (DBP) consisted of 52-week common (Part 1) and variable (Part 2) periods. Patients completing Part 1 continued into Part 2 until all patients completed Part 1, or for a maximum of 104 weeks. All patients completing Part 1 could enter the OLE and receive elafibranor.
At Week 104 in DBP Part 2, 64.3% (18/28) and 10.7% (3/28) of elafibranor-treated patients achieved biochemical response and alkaline phosphatase (ALP) normalization, respectively, vs. no placebo-treated patients. In patients with moderate-to-severe fatigue or pruritus at baseline, mean (SE) changes to Week 104 in PROMIS Fatigue Short Form 7a (PFSF 7a) and PBC Worst-Itch Numeric Rating Scale (PBC WI NRS) were -6.3 (2.2) vs. -0.4 (1.2) and -4.1 (1.0) vs. 0.3 (1.2), respectively, with elafibranor vs. placebo. A total of 138 patients entered the OLE (continuous elafibranor: n = 93; crossover elafibranor: n = 45). Among patients continuing elafibranor, 58.8% (47/80) and 65.0% (13/20) achieved biochemical response, and 15.0% (12/80) and 25.0% (5/20) achieved ALP normalization at Weeks 104 and 156, respectively. In crossover patients, 51.2% (21/41) and 22.0% (9/41) achieved biochemical response and ALP normalization after 52 weeks, respectively. In patients continuing elafibranor with moderate-to-severe symptoms at baseline, mean (SE) changes to Week 130 in PFSF 7a and PBC WI NRS were -4.8 (1.5) and -4.0 (0.7), respectively. There were no unexpected safety findings.
Through 3 years of treatment, elafibranor led to sustained biochemical improvements and was generally well tolerated, with numerical improvements in fatigue and pruritus.
Given the chronic, progressive nature of primary biliary cholangitis (PBC), the long-term efficacy and tolerability of treatments is important. Here, we present 2-year results from the double-blind period, and long-term data from the ongoing open-label extension of the phase III ELATIVE® trial, wherein elafibranor (a peroxisome proliferator-activated receptor-α/δ agonist) treatment led to sustained biochemical improvements, stable non-invasive tests of fibrosis, and numerical improvements in fatigue and pruritus, through 3 years. Elafibranor demonstrated a favorable safety profile up to a maximum treatment exposure of 3.5 years, including in patients crossing over from placebo. These findings support elafibranor as a durable long-term treatment for patients with PBC, and are particularly relevant for clinicians managing patients with inadequate response or intolerance to first-line treatments.
NCT04526665 (https://clinicaltrials.gov/study/NCT04526665); first registered 08/26/2020.
Utility of Face2Gene's DeepGestalt and D-Score applications in paediatric neurodevelopmental disorders in South Africa.
Bruwer Z, Mc Donald H, Zieff MR, Eastman E, Melly B, Sulaiman-Bardien R, Fieggen K, Moosa S, O'Heir E, Austin Tse C, Osei-Owusu I, Galvin A, van der Merwe C, O'Donnell-Luria A, Newton CR, Abubakar A, Robinson EB, Donald KA, NeuroDev Consortium · Eur J Hum Genet (2026)
South Africa · DOI: 10.1038/s41431-026-02216-5
Face2Gene is a clinical tool that leverages facial features to aid genetic diagnosis. The DeepGestalt application suggests potential diagnoses based on facial similarity, while the D-Score evaluates likelihood of an individual having dysmorphic features suggestive of a possible genetic diagnosis. Given performance variability across populations and limited data from South Africa, this study assessed clinical utility in South African children with neurodevelopmental disorders (NDDs). Facial photographs from 301 children were analysed. The cohort comprised three groups: 36 children with NDDs with confirmed molecular diagnoses, 176 with NDDs without molecular diagnoses and 89 unaffected children. Diagnostic (recognition) accuracy was measured by whether the confirmed diagnosis appeared in the top-1 or top-10 ranked algorithm-generated suggestions (DeepGestalt). D-Scores were extracted to calculate group differences. Among children with confirmed molecular diagnoses, accuracy was 19% (95% CI: 9-35%) (top-1) and 34% (95% CI: 20-52%) (top-10), improving to 33% (95% CI: 16-56%) and 61% (95% CI: 39-80%) when limited to conditions included in the DeepGestalt training set. One-way ANOVA revealed differences between participants with and without significant dysmorphic features, as assessed by clinicians. The D-Score demonstrated moderate sensitivity (78%, [95% CI: 0.64, 0.88]) and low specificity (42%, [95% CI: 0.38, 0.50]), but high negative predictive value (91%, [95% CI: 0.84, 0.95]), suggesting it may be more useful for ruling out dysmorphism; however, the low specificity indicates a high rate of false positives, even among clinically non-dysmorphic children. These findings suggest that under-representation of African populations may limit clinical performance and equity of AI-based facial phenotyping tools.
Genomic sequencing of vineyard-isolated Bacillus strains and comparison with closely related Bacillus species reveals a putative new lineage, distinct pan-genome architecture and secondary metabolism potential.
Kayode AJ, Wanjofu EI, Setati ME · Front Microbiol (2026)
South Africa · DOI: 10.3389/fmicb.2026.1871298
Bacillus species are ubiquitous in nature, and they display diverse traits of biotechnological importance, including the production of various enzymes and secondary metabolites. In this study, we profiled the genomes of vineyard-derived Bacillus strains shown to inhibit Botrytis cinerea mycelial growth and spore germination through the production of cyclic lipopeptides and cell wall-degrading enzymes.
Long-reads-whole genome sequencing was conducted using PacBio Sequel II Single-Molecule Real-Time platform, followed by genome assembly, phylogenetic analysis and functional annotation using different bioinformatics pipelines.
The strains possess ~3.900,000 bp genome size and %GC ranging between 45%-46.7%, as expected in Bacillus species. Phylogenetic analysis separated the vineyard-derived strains into two lineages. Strains B4003 and B4005 grouped with B. velezensis. Notably, three Bacillus strains (B4022, B4001, and B4023) clustered with the undescribed strains with placeholders "sp018613535", an undescribed taxon in the genome taxonomy database, supported by the Average Nucleotide Identity (ANI) score above 96%. Putative biosynthetic gene clusters (BGCs) involved in secondary metabolite production were identified by AntiSMASH analysis among the isolates. Orthologous cluster analysis further identified 3203 genes conserved across all strains, constituting a stable core genome that supports essential cellular and metabolic functions. Comparative pan-genome analysis of the Bacillus velezensis and Bacillus spp. revealed clear species-level differentiation alongside a conserved functional backbone. Furthermore, functional annotation revealed strain-specific enrichment in metabolic and environmental response pathways, emphasizing the ecological specialization and adaptive diversification.
Overall, these findings emphasize the dynamic interplay between genomic conservation and flexibility within the Bacillus genus and support the biological control potential of these strains. Furthermore, genomic evidence strongly indicates that B4001, B4022 and B4023, represent members of a putatively novel species.
Genomes of cressdnaviricots and phixviricots in a freshwater lake sample from Arizona, USA.
Custer JM, Kraberger S, Levi G, Schmidlin K, Potter KA, Rosenstein DD, Paietta EN, Žuštra A, Millerwise S, Varsani A · Microbiol Resour Announc (2026)
South Africa · DOI: 10.1128/mra.00920-26
A viral metagenomic analysis of a 40 ml water sample from a small freshwater lake near Flagstaff, Arizona, USA, resulted in the identification of 295 circular viral genome sequences. Of these, 126 are members of Cressdnaviricota and 169 of Phixviricota phyla.
Mapping the Prevalence of BRCA1 and BRCA2 Mutations in Hereditary Breast and Ovarian Cancer Across Africa: A Systematic Review and Meta-Analysis.
Milambo JPM, Chitha WW · Asian Pac J Cancer Prev (2026)
South Africa · DOI: 10.31557/APJCP.2026.27.8.2761
BRCA1 and BRCA2 gene mutations are major contributors to hereditary breast and ovarian cancer syndrome (HBOC). While mutation prevalence has been well-characterized in high-income countries, African populations remain underrepresented in genomics cancer research. Accurate prevalence data are essential for informing targeted screening, counselling, and personalized treatment strategies across the continent.
To systematically assess the prevalence and geographic distribution of pathogenic BRCA1 and BRCA2 mutations in African populations affected by HBOC, and identify opportunities to enhance genetic testing and clinical integration.
A systematic review and meta-analysis were conducted in accordance with PRISMA guidelines. PubMed, Scopus, Web of Science, and Embase were searched for studies published between January 2000 and June 2024. Studies were eligible if they reported germline BRCA1 or BRCA2 mutation data in African individuals with breast and/or ovarian cancer. Two reviewers independently screened studies, extracted data, and assessed methodological quality. Meta-analyses were performed using STATA 18 and RevMan, with fixed-effects models applied. Heterogeneity was evaluated using the I² statistic, and subgroup analyses were conducted based on gene type.
A total of 52 studies from 19 African countries were included. Most studies originated from Morocco (28.4%), Tunisia (18.9%), South Africa (14.7%), and Nigeria (11.6%). Cross-sectional designs were most common (68.4%). Sanger sequencing was used in 45.3% of studies, followed by next-generation sequencing (31.6%). The overall pooled prevalence of pathogenic BRCA1/2 mutations was 9.0% (95% CI: 7.7-10.4%). Subgroup analyses showed a higher prevalence for BRCA1 mutations (10.5%, 95% CI: 8.3-13.0%) compared to BRCA2 (5.5%, 95% CI: 4.9-6.1%). Over half of the studies did not distinguish between the two genes, highlighting a need for standardized gene-specific reporting.
There is a significant burden of pathogenic BRCA mutations in African HBOC populations, particularly BRCA1. However, gaps in geographic coverage and inconsistent reporting suggest the true burden may be underestimated. Expanding access to genetic testing, improving reporting standards, and integrating hereditary cancer screening into public health strategies are critical steps to advance precision oncology across Africa.
Acne is one of the most common dermatologic diseases in the world. It is due to the secretion of a high level of sebum that causes follicular hyperkeratinisation, alterations of the cutaneous microbiota, and inflammatory processes. One of the first-line treatments is still an antibiotic prescription, that inhibits bacterial growth and, as a consequence, lowers some of the other symptoms. Nevertheless, this high level of antibiotic prescription contributes to the increase of antibiotic resistance. Alternatives to antibiotics are thus highly required, as acne does not represent per se an infection.
In the frame of the IRGAP (Interdisciplinary Research Group on Ancient Pharmacopeias) consortium, different preparations dedicated to cutaneous ailments have been identified based on ancient traditional uses, dating back to Antiquity or Middle Ages. Among them, the combination of Aloe vera and Myrrh was widely conserved over centuries. Even though this combination is no longer in use, we wondered why this combination was so widely conserved. We considered the use of this combination of ingredients to treat acne, a case study for which both plants are still used, but separately.
The effects of both plant extracts were analyzed on the growth of different bacteria from the skin microbiota, cultivated alone or in co-culture conditions. As the skin is a rather heterologous environment, we further tested the robustness of our study by varying the experimental conditions. We further analyzed any complementary effects of these extracts on the inflammation process linked to acne.
We showed that both plant extracts have complementary effects on micro-organisms and on macrophages. Indeed, while Myrrh extracts inhibited the growth of specific skin microbiota bacteria, Aloe vera gel extracts on the opposite, favored the growth of others: the two plants could act in a complementary way to restore a healthy microbiota. Another complementarity was also observed on macrophages: while Myrrh extracts showed an anti-inflammatory effect, Aloe vera gel extracts showed an antioxidant effect.
Our results highlight the potential of the combination of Myrrh and Aloe vera to address both the dysbiosis of the skin microbiota and the inflammation associated with acne. Thus, this exploration of forgotten combinations from historical pharmacopoeias underscores the importance of revisiting past traditional knowledge as a source of innovation.
Although the physiological mechanisms underlying salt tolerance in wild barley (Hordeum maritimum) are relatively well understood, its recovery after salt stress remains poorly characterized. In this pot experiment, plants were exposed to 200 mM NaCl for 0, 15, 30, 45, or 60 days to evaluate changes in growth and water status. Wild barley exhibited high tolerance during the early stages of salt exposure, maintaining normal growth and water balance for up to 30 days. However, longer exposure reduced plant growth and leaf water content, indicating that prolonged salinity eventually compromises plant performance. To cope with salt stress, plants accumulate soluble sugars, proline, and mineral ions, helping maintain water uptake and cell hydration. Mineral ions, particularly sodium (Na+) and chloride (Cl-), contributed most to osmotic adjustment, accounting for up to 87% of the total osmotic adjustment after 60 days of treatment. Salt stress also induced structural modifications in leaf tissues that enhanced water retention and maintained cell function under saline conditions. Importantly, unlike cultivated barley, H. maritimum fully recovered after the salt treatment ended, restoring both growth and water relations. This strong recovery capacity demonstrates remarkable physiological flexibility and adaptation to changing environmental conditions. These findings highlight the adaptive advantage of wild barley in fluctuating saline environments, where efficient osmotic adjustment, flexible cell wall dynamics, and rapid recovery are key adaptive traits. From both physiological and ecological perspectives, H. maritimum represents a valuable model for studying salt tolerance mechanisms and a promising genetic resource for improving crop salinity resilience.
Genomic analysis of Echinococcus granulosus sensu stricto: genetic diversity and population structure.
Anijalg L, Korhonen PK, Young ND, Cai H, Li J, Yang H, Wang D, Wang T, Yang B, Laurimäe T, Jenkins DJ, Casulli A, Rostami-Nejad M, Acosta-Jamett G, Irshadullah M, Mirhendi H, Sharbatkhori M, Kia EB, Ponce-Gordo F, Simsek S, Zait H, de la Rue ML, Soriano SV, Lazzarini LE, Romig T, Wassermann M, Aghayan SA, Gevorgyan H, Ibrahim MM, Rehbein S, Šnábel V, Manfredi MT, Chang BCH, Saarma U, Gasser RB · Lancet Microbe (2026)
Egypt · DOI: 10.1016/j.lanmic.2026.101453
Cystic echinococcosis, caused by the tapeworm Echinococcus granulosus sensu stricto (ss), is a globally distributed, zoonotic disease that is recognised by WHO as a neglected tropical disease. Despite its clinical and economic importance, nuclear genomic variation in this parasite has not been systematically characterised across global populations. In this study, we aimed to characterise the genome-wide nuclear genetic diversity and population structure of E granulosus ss across globally distributed populations.
We conducted a genomic study of 137 E granulosus ss samples from endemic regions across five continents, derived from previously collected parasite material from livestock, wildlife, and human infections. Using a chromosome-scale reference genome, we applied population genomic approaches to investigate genome-wide nuclear genetic diversity, population structure, and patterns of evolutionary constraint.
We identified 1 071 085 nuclear single-nucleotide polymorphisms across 137 samples, with heterozygosity ranging from 46% to 93% per sample. Genome-wide analyses identified two major clades associated with geographical origin. Distinct regions of genetic differentiation were observed, particularly on chromosome 9. Conserved genes under purifying selection included those involved in glycan biosynthesis and core cellular functions, whereas variable genes were enriched in pathways such as ribosome biogenesis. Mitochondrial genotypes (G1 and G3) did not align with the nuclear genomic structure.
To the best of our knowledge, this study provides the first broad atlas of nuclear genomic diversity in E granulosus ss, uncovering genetic diversity and population structure. The findings have important implications for molecular epidemiology, genomic surveillance, and translational development of diagnostics and vaccines. Incorporating genomic data into cystic echinococcosis control programmes could enhance WHO-aligned efforts to reduce the burden of this neglected tropical disease.
Australian Research Council and the Estonian Ministry of Education and Research.
Aeromonas spp. are critical aquatic pathogens affecting global aquaculture and human health, yet their taxonomy is frequently confounded by persistent horizontal gene transfer and high recombination rates. While whole-genome sequencing offers definitive resolution, many laboratories remain dependent on biochemical profiling or multi-locus sequence typing (MLST) due to cost and infrastructure constraints. To address this diagnostic gap, a two-phase phylogenomic study to identify a robust single locus genetic marker was conducted. In the discovery phase, we analyzed 22 high-quality complete Aeromonas type strain genomes to quantify the evolutionary impact of recombination and selection of new marker candidate, followed by a validation phase involving high-quality 374 genus-wide assemblies. Our results indicate that an elevated recombination-to-mutation ratio (r/m ≈ 1.70) is associated with reduced phylogenetic congruence of standard MLST loci, including gyrB, groL, and recA. In contrast, the prc gene exhibited the highest congruence with the recombination-filtered clonal genealogy (score = 0.94). Within the 95-96% ANI species boundary, the prc gene identity consistently remained more than 97%. This observed prc stability may be associated with functional constraints related to its predicted role in the periplasm. We therefore propose that a prc gene phylogeny and sequence identity threshold of > 97% could serve as a rapid and cost-effective marker for preliminary species-level assignment and epidemiological surveillance of Aeromonas spp., particularly in settings where a whole-genome sequencing is not readily available.
Comprehensive in silico genomics analysis of global trends and host-specific emergence of aminoglycoside resistance in Staphylococcus aureus: a One-Health perspective.
El-Sehrawy AAMA, Jasim SA, Jasim HF, Nematov O, Baig MR, Smerat A, Iqbal MS, Basunduwah TS, Beig M · BMC Microbiol (2026)
Egypt · DOI: 10.1186/s12866-026-05542-2
Aminoglycosides remain clinically valuable against Staphylococcus aureus. Aminoglycoside resistance in S. aureus represents a critical One Health concern and is primarily driven by aminoglycoside-modifying enzymes (AMEs), which are frequently plasmid-encoded. Although regional studies have provided valuable insights, the global epidemiology of aminoglycoside resistance determinants remains poorly characterized because comprehensive data integrating human, animal, and environmental reservoirs are still lacking. This study addresses this gap by analyzing over 110,000 S. aureus genomes (2000-2025) to map the global resistome, quantify temporal and host-specific trends, and assess the association between genetic determinants and phenotypic resistance.
We performed a retrospective One Health meta-analysis of 110,309 S. aureus genomes collected between 2000 and 2025 from 128 countries. Genomes were quality-filtered and aminoglycoside resistance determinants were identified using NCBI AMRFinderPlus (v4.0.23). Multilocus sequence typing and host-source harmonization (Human, Animal, Environment, Unknown) enabled clonal and reservoir stratification. Temporal trends in gene prevalence and resistance burden were modeled with robust regression. Geographic and host-associated structuring of key genes was assessed via χ2 and enrichment tests. Machine-learning models (elastic-net, random forests, XGBoost) were benchmarked for minimum inhibitory concentration (MIC) prediction via nested cross-validation, with performance evaluated by mean absolute error, RMSE, and SHAP-based feature importance. All analyses were conducted in R and Python using publicly available, de-identified genomic data.
Aminoglycoside resistance-associated genes were dominated by modifying enzyme determinants, with ant(6)-Ia, ant(9)-Ia, aph(3')-IIIa, sat4, aadD1, and aac(6')-Ie/aph(2'')-Ia occurring in 14-22% of isolates worldwide. Temporal analysis revealed significant declines in several major determinants, most notably ant(9)-Ia (-2.22 percentage points per year, p < 0.001), whereas apmA exhibited a non-significant decreasing trend in animal isolates. Host structuring was marked: human clinical isolates concentrated common determinants, while animal and environmental isolates harbored rare alleles (apmA, spw, str, spd). Geographic mapping confirmed near-universal distribution of common genes but focal restriction of rare ones. Publicly available phenotypic data indicated strong activity of amikacin, whereas gentamicin showed a distinct resistant subpopulation that closely corresponded with AME gene carriage. Genotype-phenotype analyses demonstrated strong concordance, with gene-rich complements predicting resistant MIC strata and absence of determinants predicting susceptibility. Analysis across different gene classes revealed frequent co-occurrence of aminoglycoside resistance genes with determinants from other classes, such as mecA, blaZ, and MLS_B, embedding them within multidrug-resistant (MDR) genomic contexts.
Over 25 years, the prevalence of aminoglycoside resistance-associated genes in S. aureus has declined for several common determinants, while rare veterinary-linked alleles are emerging in animal isolates. Strong genotype-phenotype concordance supports genomic prediction for gentamicin and amikacin, where MIC data are available, although phenotypic confirmation remains essential. The frequent co-occurrence of aminoglycoside resistance genes with other antimicrobial resistance determinants indicates their integration within co-occurrence patterns of MDR genes, defined here as clusters of co-occurring resistance genes often carried on shared mobile genetic elements. These patterns highlight the need for integrated One Health surveillance combining clinical, veterinary, and environmental monitoring with plasmid-context resolution to anticipate emerging threats.